Docoh
Loading...

IONS Ionis Pharmaceuticals

188 patents

Page 4 of 10
APP
Utility
Conjugated Antisense Compounds and Their Use
25 Feb 21
Provided herein are oligomeric compounds with conjugate groups.
Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
Filed: 24 Feb 20
GRANT
Utility
Compositions and methods for modulating apolipoprotein C-III expression
23 Feb 21
Provided herein are oligomeric compounds with conjugate groups targeting apolipoprotein C-III (ApoCIII).
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
Filed: 7 Feb 18
GRANT
Utility
Modulators of APOL1 expression
23 Feb 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting APOL1 expression, which may be useful for treating, preventing, or ameliorating a disease associated with APOL1.
Susan M. Freier
Filed: 21 May 19
APP
Utility
Compounds and Methods for Modulating Gfap
11 Feb 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of GFAP RNA in a cell or subject, and in certain instances reducing the amount of GFAP in a cell or subject.
Berit Elissa Powers, Huynh-Hoa Bui, Susan M. Freier, Frank Rigo
Filed: 24 Jul 20
APP
Utility
Modulators of IRF4 Expression
11 Feb 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.
Tianyuan Zhou, Youngsoo Kim, Robert MacLeod, Huynh-Hoa Bui, Susan M. Freier
Filed: 1 Mar 19
APP
Utility
Compounds and Methods for the Modulation of Amyloid-beta Precursor Protein
11 Feb 21
Certain embodiments disclosed herein are directed to compounds and methods for modulating APP expression.
Frank Rigo, Michelle Hastings
Filed: 1 Mar 19
GRANT
Utility
Compounds and methods for modulating angiotensinogen expression
9 Feb 21
Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating AGT and modulating a RAAS pathway related disease, disorder and/or condition in an individual in need thereof.
Adam Mullick, Mark J. Graham, Punit P. Seth, Susan M. Freier
Filed: 7 Oct 16
GRANT
Utility
Methods for reducing LRRK2 expression
2 Feb 21
Provided herein are methods for decreasing LRRK2 mRNA expression.
Hien Thuy Zhao, Holly Kordasiewicz
Filed: 5 Jan 17
APP
Utility
Compositions and Methods for Modulating TTR Expression
28 Jan 21
Provided herein are oligomeric compounds with conjugate groups.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 13 Feb 20
APP
Utility
Modified Compounds and Uses Thereof
21 Jan 21
The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications.
Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
Filed: 12 Feb 19
APP
Utility
Compositions and Their Uses Directed to Huntingtin
21 Jan 21
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal.
Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
Filed: 10 Aug 20
APP
Utility
Modulation of HSD17B13 Expression
6 Jan 21
Provided herein are methods, compounds, and compositions for reducing expression of HSD17B13 in a cell or individual.
Susan F. Murray, Jiangwei Zhang, Huynh-Hoa Bui
Filed: 20 Mar 19
APP
Utility
Selective Antisense Compounds and Uses Thereof
6 Jan 21
The present invention provides oligomeric compounds.
Michael Oestergaard, Punit P. Seth, Eric E. Swayze
Filed: 17 Feb 20
APP
Utility
Methods and Compositions for Modulating Apolipoprotein (A) Expression
6 Jan 21
Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a).
Rosanne M. Crooke, Mark J. Graham, Susan M. Freier, Marc Lim, Andrew Dibble
Filed: 2 Aug 20
APP
Utility
Methods for Modulating FMR1 Expression
6 Jan 21
Provided are methods for increasing the amount or activity of FMR1 RNA, and in certain instances of increasing the amount of FMRP protein, in an animal Such methods are useful to prevent or ameliorate at least one symptom of a Fragile X-Spectrum disorder.
Frank RIGO, Peter TODD, Caitlin RODRIGUEZ
Filed: 21 Mar 19
GRANT
Utility
Compositions and methods for modulating apolipoprotein (a) expression
4 Jan 21
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)].
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
Filed: 6 Feb 18
APP
Utility
Methods of Modulating Antisense Activity
30 Dec 20
Disclosed herein are methods for increasing antisense activity by modulating EGFR.
Shiyu Wang, Alexey Revenko, Xue-hai Liang, Stanley T. Crooke
Filed: 12 Feb 19
GRANT
Utility
Compositions and methods for modulating angiopoietin-like 3 expression
28 Dec 20
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
Filed: 25 Feb 18
APP
Utility
Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
16 Dec 20
The present invention provides oligomeric compounds.
Susan M. Freier, Eric E. Swayze
Filed: 20 Jan 20
APP
Utility
Compounds and Methods for Reducing Snca Expression
16 Dec 20
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SNCA mRNA in a cell or animal, and in certain instances reducing the amount of alpha-synuclein protein in a cell or animal.
Holly Kordasiewicz, Priyam Singh, Susan M. Freier, Tracy A. Cole
Filed: 8 Nov 18
Patents are sorted by USPTO publication date, most recent first